- Home
- PLRX
as 07-26-2024 4:00pm EST
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 684.7M | IPO Year: | 2020 |
| Target Price: | $46.00 | AVG Volume (30 days): | 695.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.29 - $20.23 | Next Earning Date: | 08-07-2024 |
| Revenue: | $248,000 | Revenue Growth: | -97.46% |
| Revenue Growth (this year): | -63.56% | Revenue Growth (next year): | 466.41% |
Stock Insider Trading Activity of Pliant Therapeutics Inc. (PLRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ouimette Mike | PLRX | General Counsel & Corp. Sec'y | Jul 10 '24 | Sell | $11.56 | 7,656 | $88,503.36 | 94,044 | SEC Form 4 |
| Cummings Keith Lamont | PLRX | Chief Financial Officer | Jul 10 '24 | Sell | $11.56 | 10,911 | $126,131.16 | 282,115 | SEC Form 4 |
| Lefebvre Eric | PLRX | Chief Medical Officer | Jul 10 '24 | Sell | $11.56 | 12,319 | $142,407.64 | 213,052 | SEC Form 4 |
| Cummings Keith Lamont | PLRX | Chief Financial Officer | Jan 17 '24 | Sell | $17.23 | 9,781 | $168,526.63 | 194,605 | SEC Form 4 |
| Coulie Bernard | PLRX | President and CEO | Jan 17 '24 | Sell | $17.23 | 25,721 | $443,172.83 | 316,382 | SEC Form 4 |
| Ouimette Mike | PLRX | General Counsel & Corp. Sec'y | Jan 17 '24 | Sell | $17.23 | 5,197 | $89,544.31 | 55,246 | SEC Form 4 |
| Lefebvre Eric | PLRX | Chief Medical Officer | Jan 17 '24 | Sell | $17.23 | 10,295 | $177,382.85 | 156,920 | SEC Form 4 |
| Hull Hans | PLRX | Chief Business Officer | Jan 17 '24 | Sell | $17.23 | 9,786 | $168,612.78 | 185,069 | SEC Form 4 |
Latest Pliant Therapeutics Inc. News
PLRX Breaking Stock News: Dive into PLRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
GlobeNewswire
a month ago
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewswire
a month ago
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities
Motley Fool
2 months ago
2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)
CNW Group
2 months ago
DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans
Investor's Business Daily
2 months ago
Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike
CNW Group
2 months ago
EPCOR and HAWSCo Enter Ownership Transfer Agreement
Compare PLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLRX Pliant Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.